BLSM Stock Summary and Trading Ideas (Blossomhill Therapeutics | NASDAQ:BLSM)

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.

What symbol and exchange does Blossomhill Therapeutics shares trade?

Blossomhill Therapeutics trades on the NASDAQ stock market under the symbol BLSM.

What is Blossomhill Therapeutics stock price doing today?

As of October 2, 2026, BLSM stock price climbed to $19.69 with 167,550 million shares trading.

How much is Blossomhill Therapeutics worth?

BLSM has a market cap of $625.84 million. This is considered a Small Cap stock.

What are the top ETFs holding Blossomhill Therapeutics?

The top ETF exchange traded funds that BLSM belongs to (by Net Assets): VTI, VXF, VTWO, VTWG, VTWV.

What are the support and resistance levels for Blossomhill Therapeutics (BLSM)?

BLSM support price is $17.33 and resistance is $19.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLSM shares will trade within this expected range on the day.